Business Context and Reporting Period
Company: GAXOS.AI INC. (Nasdaq: GXAI)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2024
Corporate Status: Emerging Growth Company; Smaller Reporting Company; Non-accelerated filer.
Operations: The Company is a technology-based entity developing AI applications for health and entertainment. Key segments include Gaxos Labs (generative AI for game developers), Gaxos Gaming (AI-integrated games and NFTs), and Gaxos Health (AI-driven wellness solutions). In late 2024, the Company formed RNK Health LLC (70% owned) to market GLP-1 medications.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenues | $4,027 | $256 |
| Operating Expenses | $3,707,632 | $4,015,541 |
| Net Loss | $(3,424,283) | $(3,948,097) |
| Net Loss Per Share (Basic/Diluted) | $(1.92) | $(3.90) |
| Cash and Cash Equivalents (Year End) | $14,398,099 | $1,024,710 |
| Short-Term Investments | $2,167,419 | $2,592,689 |
| Working Capital | $16,427,618 | $3,372,503 |
| Total Liabilities | $401,507 | $270,036 |
Note: The filing text does not provide explicit gross margin or operating margin percentages due to negligible revenue relative to expenses.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased to $4,027 from $256, driven primarily by the launch of health coaching packages ($3,952) and Gaxos Labs subscriptions ($42). Gaming revenue remained minimal ($33).
- Expense Reduction: Total operating expenses decreased by 7.7% to $3.7 million. This was primarily due to a $559,528 decrease in compensation (driven by lower stock-based compensation accretion) and the absence of a $52,363 impairment loss recorded in 2023 related to a terminated Columbia University license.
- Liquidity Expansion: Cash balances surged from $1.0 million to $14.4 million. This increase was fueled by significant financing activities, including two registered direct offerings in December 2024 and warrant exercises, generating over $16.5 million in net cash from financing.
- Capital Structure: The Company completed a 1-for-12 reverse stock split in March 2024 and reincorporated from Delaware to Nevada in March 2025.
Outlook, Risks, and Management Commentary
- Guidance: Management does not provide specific numerical guidance. They anticipate continuing to generate operating losses in the foreseeable future due to corporate overhead, R&D, and public company costs. They believe current cash and working capital are sufficient for operations for the next 12 months.
- Strategic Focus: Continued development of Gaxos Labs, Gaxos Gaming, and Gaxos Health. Expansion of RNK Health to include testosterone replacement therapy (TRT).
- Key Risks:
- Going Concern: While currently liquid, the Company has a limited operating history and has not generated sustainable revenue. Future financing may be required.
- Regulatory Uncertainty: Significant risks regarding the classification of NFTs as securities, cryptocurrency regulations, and healthcare compliance (HIPAA, GLP-1 marketing).
- Market Volatility: Dependence on the volatile NFT and cryptocurrency markets; potential delisting from Nasdaq if bid price requirements are not met.
- Competition: Intense competition from major gaming and health tech players with superior resources.
- Unusual Items: In 2023, the Company recorded a $52,363 impairment loss on intangible assets. No such loss was recorded in 2024.
Investor Verification Checklist
- Revenue Sustainability: Verify the recurring nature of the $4,027 in revenue, specifically the health coaching and subscription models, to assess if this is a scalable business model.
- Cash Burn Rate: Confirm the $3.28 million net cash used in operating activities and validate the 12-month runway estimate provided by management.
- Financing Dilution: Review the terms of the December 2024 registered direct offerings and the associated warrants to understand potential future dilution.
- Regulatory Compliance: Investigate the specific regulatory status of RNK Health's GLP-1 marketing and the Company's NFT platform regarding securities laws.
- Stock-Based Compensation: Monitor future stock-based compensation expenses, which dropped significantly in 2024 but may rise with new grants.